Abstract
Numerous serologic immunoassays have been launched to detect antibodies to SARS-CoV-2, including rapid tests. This study validates the use of a lateral flow immunoassay (LFI) intended for rapid screening and qualitative detection of anti-SARS-CoV-2 IgM and IgG in serum, plasma, and whole blood, comparing results with the gold-standard ELISA. We also seek to establish the value of LFI testing on blood obtained from capillary finger-stick samples. Our results show that the Biolidics LFI kit achieves a clinical sensitivity of 92% at seven days post-PCR diagnosis. Furthermore, capillary blood showed a 93% sensitivity for antibody detection, comparable to venous blood. These findings suggest that LFI provides an opportunity for decentralized rapid testing and longitudinal self-monitoring for SARS-CoV-2 exposure.
Introduction
During the early stages of the COVID-19 pandemic, RT-qPCR served as the primary diagnostic tool for identifying active infections. However, PCR testing requires specialized laboratory infrastructure, invasive nasopharyngeal swabs, and fails to identify individuals who have recovered from past infections. Serological tests, which detect antibodies, fill this diagnostic gap by identifying past exposure and potential immunity.
While Enzyme-Linked Immunosorbent Assays (ELISA) are the laboratory standard for antibody detection, they are time-consuming and require trained personnel. Lateral flow immunoassays (LFIs) offer a rapid, decentralized alternative. This study addresses the critical need for rigorous validation of these rapid tests, specifically evaluating whether they can reliably utilize capillary blood from a finger-stick—a method far more accessible for point-of-care and community screening than traditional venous blood draws.
Methods
The researchers conducted a retrospective validation of the Biolidics 2019-nCoV IgG/IgM Detection Kit (Colloidal Gold). The LFI's performance was benchmarked against an in-house ELISA developed by MGH/Ragon.
The methodology focused on three primary areas:
- Matrix Comparison: The LFI was tested across four sample types: serum, plasma, venous whole blood, and capillary finger-stick blood to ensure consistency across media.
- Temporal Analysis: Sensitivity was evaluated at two distinct time points: "Day 0" (the day of a positive PCR result) and "Day 7" (seven or more days post-diagnosis).
- Observer Verification: To mitigate the subjectivity inherent in visual tests, each LFI result was interpreted by two independent observers.
Datasets
The study utilized samples from 62 patients at NYU Langone Medical Center, categorized into three cohorts:
- Positive Cohort: 39 patients with RT-qPCR-confirmed SARS-CoV-2.
- Negative Control Cohort: 24 patients, including 20 archived plasma samples from early 2019 (pre-pandemic) to assess cross-reactivity and 4 samples from March 2020 from PCR-negative patients.
- Capillary Cohort: 14 recovered COVID-19 patients (18–46 days post-diagnosis) specifically recruited for finger-stick validation.
Key Results
Temporal Sensitivity and Specificity
The study revealed that the timing of the test is paramount. At the time of initial PCR diagnosis (Day 0), sensitivity was only 29%. however, this jumped to 92% at seven or more days post-diagnosis. This confirms that LFIs are most effective as exposure screening tools rather than acute diagnostic tools, as the body requires time to mount a detectable immune response.
Regarding specificity, the LFI achieved 100% for IgG antibodies. IgM specificity was slightly lower at 92%, with some false positives observed in pre-COVID-19 samples. This suggests that IgG is the more dependable marker for confirming prior exposure.
Capillary vs. Venous Blood
A primary finding of the study was the high performance of capillary blood. Finger-stick samples from recovered patients showed a 93% sensitivity for antibody detection. Statistical analysis showed no significant difference in performance between the LFI and ELISA at Day 0 or Day 7 (p=1.00), with the minor exception of IgM detection at Day 7 (p=0.04).
Matrix Consistency
Results were consistent across plasma and whole blood. This is a significant practical finding, as it suggests laboratories can bypass the time-consuming step of centrifuge-separating plasma, further accelerating the testing pipeline.
Discussion and Limitations
The validation of finger-stick capillary blood for LFI testing opens the door for decentralized, point-of-care, and potentially self-administered testing. The strong correlation between positive LFI results and high antibody titers in ELISA suggests that these rapid tests effectively identify individuals with robust immune responses.
However, several limitations remain:
- Sample Size: The capillary validation cohort was small (n=14), requiring larger studies for broader confirmation.
- Immunity vs. Exposure: The presence of antibodies, while indicative of exposure, does not yet strictly guarantee protective immunity against reinfection.
- Kinetic Variability: The researchers noted significant inter-individual variability in antibody production, even among household members with similar symptoms.
- Subjectivity: Because LFIs rely on visual interpretation of faint bands, future iterations might benefit from AI-assisted image analysis to eliminate human error.
Conclusion
The Biolidics 2019-nCoV IgG/IgM Detection Kit demonstrates clinical performance comparable to ELISA, particularly when administered at least one week after symptom onset or diagnosis. The confirmation that capillary blood provides similar sensitivity to venous blood supports the transition toward more accessible, community-based screening and longitudinal monitoring of SARS-CoV-2 exposure.
Summary updated